Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics

authors

• Silvy Florent
• Bertin Daniel
• Bardin Nathalie
• Auger Isabelle
• Guzian Marie-Caroline
• Mattei Jean-Pierre
• Guis Sandrine
• Roudier Jean
• Balandraud Nathalie

keywords

• INFLIXIMAB
• AUTOANTIBODY INDUCTION
• CASPAR CRITERIA
• CITRULLINATED PEPTIDE ANTIBODIES
• RHEUMATOID-ARTHRITIS
• CLASSIFICATION CRITERIA
• SPONDYLOARTHRITIS
• AUTOIMMUNITY

abstract

Background:With the emergence of biotherapies, accurate diagnosis in early arthritis is needed. At this time, there is no biological marker of psoriatic arthritis. Objective:To test whether antinuclear antibodies (ANA) can be used as a diagnostic tool in psoriatic arthritis (PsA), we evaluated the prevalence of ANA in biologic-naïve PsA patients and in healthy blood donors. Methods:232 patients from the Rheumatology department, St Marguerite's Hospital, Marseilles, who fulfilled the CASPAR criteria for PsA, underwent clinical and laboratory investigations. Antinuclear antibodies (ANA), anti-extractable nuclear antigen antibodies (ENA), rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) were assayed. Ninety-one healthy blood donors were also tested. Results:Detection of ANA by indirect immunofluorescence was significantly more frequent in sera from PsA patients than those from controls at serum dilution of 1:100 (57% compared with 40%, Odds Ratio (OR) 1.98 (1.2-3.4) p<0.02) and 1:160 (52% compared with 24%, OR 3,7 (1.9-7.2) p<0.001). No patients had lupus specific autoantibodies, 15 % had RF (34/232), and 1.7 % had ACPA (4/232). Conclusions:Detection of ANA was more frequent in sera from PsA patients than in those from healthy controls. This suggests that ANA could be a diagnosis orientation tool in PsA. Nevertheless, the specificity of these antibodies still remains to be investigated.

more information